Chemoresistance in falciparum malaria

Trends in Parasitology

Volumn 19, Issue 10, 2003, Pages 432-435

  May, Jürgen ^a   Meyer, Christian G ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ATOVAQUONE; BENFLUMETOL; CYCLOGUANIL; DAPSONE; FOLIC ACID ANTAGONIST; GLUTATHIONE; MEFLOQUINE; MOLECULAR MARKER; PROGUANIL; PROTEIN DERIVATIVE; PYRIMETHAMINE; QUININE; SULFADOXINE; SULFANILAMIDE DERIVATIVE; SYNTHETASE; TRIPEPTIDE; VERAPAMIL;

AFRICA; ALLELE; ANTIBIOTIC RESISTANCE; BINDING AFFINITY; CHROMOSOME 4; CODON; DRUG BINDING; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG SYNTHESIS; ELECTRON TRANSPORT; EPIDEMIC; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFECTION PREVENTION; MALARIA FALCIPARUM; MOLECULAR MECHANICS; MORTALITY; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PLASMODIUM FALCIPARUM; REVIEW;

CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0242716179     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.08.001     Document Type: Short Survey

References (28)

1. Le Bras J., Durand R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam. Clin. Pharmacol. 17:2003;147-153.
2. Hastings I.M., et al. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357:2002;505-519.
3. White N.J. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 41:1999;301-308.
4. Shulman C.E., et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 353:1999;632-636.
5. Schellenberg D., et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 357:2001;1471-1477.
6. Bonhoeffer S., et al. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12106-12111.
7. WHO. Monitoring Antimalarial Drug Resistance. 2001;World Health Organization.
8. White N.J. The assessment of antimalarial drug efficacy. Trends Parasitol. 18:2002;458-464.
9. Koella J., Antia R. Epidemiological models for the spread of anti-malarial resistance. Malaria J. 2:2003;3.
10. Fidock D.A., et al. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum. Mol. Biochem. Parasitol. 110:2000;1-10.
11. Djimde A., et al. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:2001;257-263.
12. Basco L.K., Ringwald P. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J. Infect. Dis. 183:2001;1828-1831.
13. May J., Meyer C.G. Association of Plasmodium falciparum chloroquine resistance transporter variant T76 with age-related plasma chloroquine levels. Am. J. Trop. Med. Hyg. 68:2003;143-146.
14. Sidhu A.B., et al. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 298:2002;210-213.
15. Wootton J.C., et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature. 418:2002;320-323.
16. Hastings I.M., et al. Parasitology. A requiem for chloroquine. Science. 298:2002;74-75.
17. Reed M.B., et al. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 403:2000;906-909.
18. Peters J.M., et al. Mutations in Cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob. Agents Chemother. 46:2002;2435-2441.
19. Duraisingh M.T., et al. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108:2000;13-23.
20. Cowman A.F., et al. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. U. S. A. 91:1994;1143-1147.
21. Plowe C.V., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 176:1997;1590-1596.
22. Thaithong S., et al. Plasmodium falciparum: gene mutations and amplification of dihydrofolate reductase genes in parasites grown in vitro in presence of pyrimethamine. Exp. Parasitol. 98:2001;59-70.
23. Yuvaniyama J., et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 10:2003;357-365.
24. Triglia T., et al. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 17:1998;3807-3815.
25. Wang P., et al. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol. Microbiol. 32:1999;1254-1262.
26. Gogtay N.J., et al. Probable resistance to parenteral artemether in Plasmodium falciparum: case reports from Mumbai (Bombay), India. Ann. Trop. Med. Parasitol. 94:2000;519-520.
27. Korsinczky M., et al. Mutations in Plasmodium falciparum Cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44:2000;2100-2108.
28. Ginsburg H., et al. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem. Pharmacol. 56:1998;1305-1313.